Education

M.D., 1989, Shanghai Medical University, China
M.S., 1994, Immunology, Shanghai Medical University, China
Ph.D., 2006, Immunology, Fudan University, China.

Work experience

Visiting Scholar, 1995-1997, Univeristy of Washington, Seattle, USA
Visiting Scholar, 1997-1998, EACRI Cancer Center, Portland, USA
Visiting Professor, 2003-2004, EACRI Cancer Center, Portland, USA
Assist/Asso Professor, 1994-2007, Shanghai Medical University, China
Professor, 2007–present, Fudan University, China
Vice president, 2019-present, Chinese Society for Immunology(CSI)

Contact

Institutes of Biomedical Sciences, Fudan University, Shanghai 200032

Department of Immunology, Shanghai Medical College, Fudan University, Shanghai 200032

Tel: +86-21-54237350; +86-21-54237362

E.mail: yiweichu@fudan.edu.cn

Lab homepage: http://brc.fudan.edu.cn

Biography

Professor Chu holds MD and MS from Shanghai Medical University and PhD in Immunology from Fudan University in China. She was a visiting scholar in University of Washington, Seattle, USA from 1995-1998, and a visiting professor in Earle A Chiles Research Institute, Portland, Oregon, USA in 2003-2004. Focusing on tumor immunotherapy, she has conducted several outstanding studies, received over 10 grants from the National Science Foundation of China and Ministry of Science and Technology, and published over 160 scientific papers in Journals such as Immunity, Gastroenterology, Hepatology, Cell Research, PNAS, Clinical Cancer Researh, Cancer Immunol Research. She wrote 9 Chinese/English books as the chief editor and holds5authorized patents in China. She is a supervisory scientists and team leader, and has served in many professional organizations, including IUIS (International Union of Immunology Society) General Assembly Representative, 17^th ICI (IUIS 2019) scientific program committee member, vice president of CSI (Chinese Society for Immunology), Chairman of committee for infection & immunity for SCI (Shanghai Society for Immunology). She is the chairman of Committee for Woman Scientists in CSI. She leads more than 6,000 women membership for academic and teaching in annual meeting and various activities.

Research Areas：

Cancer Immunology and Immunotherapy
Regulatory B-lymphocyte in Disease

Research interest

Our lab has two main research focuses. The first is cancer immunology and immunotherapy, with a major translational focus on ex vivo chimeric antigen receptor (CAR)- or bispecific T cell engager (BiTE)-engineered T cell for cancer therapy, and aims to develop novel ways to enhance the ability of CAR-T / BiTE-T cells to recognize and eliminate cancer cells. The second focuses on the regulatory B-lymphocyte (Breg), trying to uncover the unique Breg subset and the molecular basis of Breg function in disease such as autoimmune disease and cancer. We have achieved breakthroughs in Breg subsets, phenotype, function, mechanism, drivers and clinical significance, and plan to find the potential metabolic and epigenetic targets for limiting Breg in disease. Based on the concept of translational medicine, we study the cellular immune functions in disease, consequently provides the potential immunotherapy strategies.

Selected Publications

Zhiqiang Wang, Zhou Lu, Shengli lin, Jie Xia, Ziwen Zhong, Zhangjuan Xie, Yun Xing, Jingbo Qie, Mengxia Jiao, Yifan Li, Haoyu Wen, Pengyuan Zhao, Dan Zhang, Pinghong Zhou, Jiawen Qian, Feifei Luo, Luman Wang, Hongxiu Yu, Jie Liu, Jie Gu, Ronghua Liu*, Yiwei Chu *. Leucine tRNA Synthase-2 Expressing B Cells Contribute to Colorectal Cancer Immunoevasion.Immunity.2022; 55(6):1067-1081.e8.
Zhou Lu, Ronghua Liu, Yining Wang, Mengxia Jiao, Zhongchen Li, Zhiqiang Wang, Cheng Huang, Guoming Shi, Aiwu Ke, Luman Wang, Ying Fu, Jie Xia, Haoyu Wen, Jian Zhou, Xiaoying Wang, Dan Ye, Jia Fan*, Yiwei Chu*, Jiabin Cai *. Ten-eleven translocation-2 inactivation restrains IL-10-producing regulatory B cells to enable antitumor immunity in hepatocellular carcinoma. Hepatology. 2022; doi: 10.1002/hep.32442.
Yuedi Wang, Yiyuan Gao, Congyi Niu, Bo Wang, Shushu Zhao, Gils Roex, Jiawen Qian, Jingbo Qie, Lin Chen, Chenhe Yi, Sébastien Anguille, Jie Liu*, Feifei Luo*, Yiwei Chu *. Chimeric antigen receptor clustering via cysteines enhances T-cell efficacy against tumor. Cancer Immunol Immunother. 2022; doi: 10.1007/s00262-022-03195-4.
Wanwei Zheng, Huan Song, Zhongguang Luo, Hao Wu, Lin Chen, Yuedi Wang Haoshu Cui, Yufei Zhang, Bangting Wang, Wenshuai Li, Yao Liu, Jun Zhang, Yiwei Chu*, Feifei Luo*, Jie Liu*. Acetylcholine ameliorates colitis by promoting IL-10 secretion of monocytic myeloid-derived suppressor cells through the nAChR/ERK pathway. PNAS. 2021;118(11):e2017762118
Qian J, Luo F, Yang J, Liu J, Liu R, Wang L, Wang C, Deng Y, Lu Z, Wang Y, Lu M, Wang JY, Chu Y*. TLR2 Promotes Glioma Immune Evasion by Downregulating MHC Class II Molecules in Microglia. Cancer Immunol Research. 2018; 6(10):1220-1233.
Liu R, Lu Z, Gu J, Liu J, Huang E, Liu X, Wang L, Yang J, Deng Y, Qian J, Luo F, Wang Z, Zhang H, Jiang X, Zhang D, Qian J, Liu G, Zhu H, Qian Y, Liu Z, Chu Y*. MicroRNAs 15A and 16-1 Activate Signaling Pathways That Mediate Chemotaxis of Immune Regulatory B cells to Colorectal Tumors. Gastroenterology. 2018;154(3):637-651.
Lu Z, Liu J, Liu X, Huang E, Yang J, Qian J, Zhang D, Liu R, Chu Y*. MiR-15a/16-1 Suppresses AHR-dependent IL-22 Secretion in CD4+ T cells and Contributes to Immune-mediated Organ Injury. Hepatology. 2018; 67(3):1027-1040.
Luo F, Qian J, Yang J, Deng Y, Zheng X, Liu J, Chu Y*. Bifunctional αHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2(+) gastric cancer. Cell Research. 2016; 26(7):850-3.
Liu X, Jiang X, Liu R, Wang L, Qian T, Zheng Y, Deng Y, Huang E, Xu F, Chu Y*. B cells expressing CD11b effectively inhibit CD4+ T cell responses and ameliorate experimental autoimmune hepatitis in mice. Hepatology. 2015; 62(5):1563-75.
L Wang, A Ray, X Jiang, J-y Wang, S Basu, X Liu, T Qian, R He, BN Dittel and Y Chu*. T regulatory cells and B cells cooperate to form a regulatory loop that maintains gut homeostasis and suppresses dextran sulfate sodium-induced colitis. Mucosal Immunology. 2015; 8(6):1297-312.
Ronghua Liu, Jie Gu, Pei Jiang, Yijie Zheng, Xiaoming Liu, Xuechao Jiang, Enyu Huang, Shudao Xiong,Fengkai Xu, Guangwei Liu, Di Ge, Yiwei Chu*. DNMT1-microRNA126 epigenetic circuit contributes to esophageal squamous cell carcinoma growth via ADAM9-EGFR-AKT signaling. Clinical Cancer Research, 2015; 21(4):854-63.
Zhang, Feifei Luo, Yuchan Cai, Nan Liu, Luman Wang, Damo Xu and Chu Yiwei *. TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. Journal of Immunology. 2011; 186(4): 1963-9.